Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation

Filip Janku, Faye M. Johnson, Mateusz Opyrchal, Afshin Dowlati, Cinta Hierro, Martin Forester, Sarah P. Blagden, Andreas Wicki, Debora Schmitz, Alex A. Adjei

Mol Cancer Ther (2019) 18 (12_Supplement): B109.

https://doi.org/10.1158/1535-7163.TARG-19-B109

Published: 01 December 2019

View article titled, Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation

Journal Articles

Abstract LB-B05: MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations

Sabrina Arena, Giulia Siravegna, Benedetta Mussolin, Jeffrey D. Kearns, Beni B. Wolf, Sandra Misale, Luca Lazzari, Andrea Bertotti, Livio Trusolino, Alex A. Adjei, Clara Montagut, Federica Di Nicolantonio, Rachel Nering, Alberto Bardelli

Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-B05.

https://doi.org/10.1158/1535-7163.TARG-15-LB-B05

Published: 01 December 2015

View article titled, Abstract LB-B05: MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations

Journal Articles

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Ravi K. Amaravadi, Russell J. Schilder, Lainie P. Martin, Myron Levin, Martin A. Graham, David E. Weng, Alex A. Adjei

Mol Cancer Ther (2015) 14 (11): 2569–2575.

https://doi.org/10.1158/1535-7163.MCT-15-0475

Published: 03 November 2015

View article titled, A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Includes: Supplementary data

Journal Articles

Abstract A88: Safety, pharmacokinetic, and pharmacodynamic results of BAY 86–9766, an oral MEK inhibitor, in combination with sorafenib, an oral multikinase inhibitor, in advanced cancer patients.

Alex A. Adjei, Donald A. Richards, Anthony El-Khoueiry, Carlos H.R. Becerra, Joe J. Stephenson, Jr., Diane P. Leffingwell, Cory Iverson, Jeffrey N. Miner, Zancong Shen, Sonny Gunawan, David Wilson, Kimberly J. Manhard, Ron L. Dubowy, Michael Jeffers, Prabhu Rajagopalan, Wilbur A. Franklin, Jerry Haney, Patricia Lenhart, Neil J. Clendeninn

Mol Cancer Ther (2011) 10 (11_Supplement): A88.

https://doi.org/10.1158/1535-7163.TARG-11-A88

Published: 12 November 2011

View article titled, Abstract A88: Safety, pharmacokinetic, and pharmacodynamic results of BAY 86–9766, an oral MEK inhibitor, in combination with sorafenib, an oral multikinase inhibitor, in advanced cancer patients.

Journal Articles

Abstract C228: Renal insufficiency secondary to Erlotinib: Is it real?

Sumbal Nabi, Alex A. Adjei, Joseph Prah, Nithya Ramnath, James Schwartz, Kevin Lennon, Michele Silsby Grabek, Grace K. Dy

Mol Cancer Ther (2009) 8 (12_Supplement): C228.

https://doi.org/10.1158/1535-7163.TARG-09-C228

Published: 10 December 2009

View article titled, Abstract C228: Renal insufficiency secondary to Erlotinib: Is it real?

Journal Articles

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

Judith A. Gilbert, Matthew P. Goetz, Carol A. Reynolds, James N. Ingle, Karin F. Giordano, Vera J. Suman, Hilary E. Blair, Robert B. Jenkins, Wilma L. Lingle, Monica M. Reinholz, Alex A. Adjei, Matthew M. Ames

Mol Cancer Ther (2008) 7 (4): 944–951.

https://doi.org/10.1158/1535-7163.MCT-07-0570

Published: 15 April 2008

View article titled, Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

Journal Articles

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH₂-terminal kinase pathways

Chunrong Yu, Bret B. Friday, Jin-Ping Lai, Lin Yang, Jann Sarkaria, Neil E. Kay, Christopher A. Carter, Lewis R. Roberts, Scott H. Kaufmann, Alex A. Adjei

Mol Cancer Ther (2006) 5 (9): 2378–2387.

https://doi.org/10.1158/1535-7163.MCT-06-0235

Published: 19 September 2006

View article titled, Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways

NARROW

Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation

Abstract LB-B05: MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Abstract A88: Safety, pharmacokinetic, and pharmacodynamic results of BAY 86–9766, an oral MEK inhibitor, in combination with sorafenib, an oral multikinase inhibitor, in advanced cancer patients.

Abstract C228: Renal insufficiency secondary to Erlotinib: Is it real?

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH₂-terminal kinase pathways

Email alerts

AACR Journals

Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation

Abstract LB-B05: MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma

Abstract A88: Safety, pharmacokinetic, and pharmacodynamic results of BAY 86–9766, an oral MEK inhibitor, in combination with sorafenib, an oral multikinase inhibitor, in advanced cancer patients.

Abstract C228: Renal insufficiency secondary to Erlotinib: Is it real?

Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH₂-terminal kinase pathways